Amedisys 과거 수익 실적

NasdaqGS:AMED 수익, 비용 및 수입 (USD Millions )
날짜	수익	수익	G+A 비용
30 Jun 24	2,290	92	782
31 Mar 24	2,251	-21	780
31 Dec 23	2,236	-10	780
30 Sep 23	2,228	3	774
30 Jun 23	2,229	2	769
31 Mar 23	2,234	112	763
31 Dec 22	2,223	119	754
30 Sep 22	2,220	121	745
30 Jun 22	2,216	140	736
31 Mar 22	2,222	191	723
31 Dec 21	2,214	209	711
30 Sep 21	2,206	220	1,033
30 Jun 21	2,196	247	911
31 Mar 21	2,117	202	785
31 Dec 20	2,072	184	668
30 Sep 20	2,021	166	216
30 Jun 20	1,972	128	214
31 Mar 20	1,980	127	219
31 Dec 19	1,956	127	608
30 Sep 19	1,889	127	207
30 Jun 19	1,812	124	197
31 Mar 19	1,731	123	189
31 Dec 18	1,663	119	185
30 Sep 18	1,626	88	181
30 Jun 18	1,583	71	178
31 Mar 18	1,546	42	178
31 Dec 17	1,511	30	177
30 Sep 17	1,474	43	181
30 Jun 17	1,456	40	187
31 Mar 17	1,438	46	190
31 Dec 16	1,419	37	196
30 Sep 16	1,391	41	198
30 Jun 16	1,358	38	193
31 Mar 16	1,313	38	188
31 Dec 15	1,266	-3	173
30 Sep 15	1,230	-7	158
30 Jun 15	1,204	-7	149
31 Mar 15	1,193	-10	142
31 Dec 14	1,188	13	147
30 Sep 14	1,191	-4	153
30 Jun 14	1,192	-103	161
31 Mar 14	1,203	-109	167
31 Dec 13	1,233	-93	170

양질의 수익: AMED 에는 $49.1M 큰 일회성 손실이 있습니다. $49.1M 은 지난 12개월 간의 재무 결과에 30th June, 2024 까지 영향을 미쳤습니다.

이익 마진 증가: AMED 의 현재 순이익 이익률 (4%) 작년보다 높습니다 (0.1%).

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: AMED 의 수입은 지난 5년 동안 매년 22% 씩 감소했습니다.

성장 가속화: 지난 1년간 AMED 의 수익 증가율( 3847.8% )은 연간 평균( -22% 초과합니다. ).

수익 대 산업: 지난 1년간 AMED 수익 증가율( 3847.8% )은 Healthcare 업계 11.4% 초과했습니다.

Amedisys 과거 수익 실적

과거 기준 확인 3/6

주요 정보

최근 과거 실적 업데이트

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

First quarter 2024 earnings: EPS misses analyst expectations

Full year 2023 earnings: EPS misses analyst expectations

Third quarter 2023 earnings: EPS misses analyst expectations

Full year 2022 earnings: EPS exceeds analyst expectations

Amedisys, Inc. to Report Q4, 2022 Results on Feb 15, 2023

Recent updates

Final Push For Amedisys As UnitedHealth Awaits Regulatory Clearance

Michael P. North Leaves Amedisys, Inc. as Chief Information Officer and Compensation Committee of the Board of Directors, Effective August 31, 2024

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

First quarter 2024 earnings: EPS misses analyst expectations

Full year 2023 earnings: EPS misses analyst expectations

Insufficient new directors

President notifies of intention to sell stock

Consensus EPS estimates fall by 54%

Third quarter 2023 earnings: EPS misses analyst expectations

Option Care Health, Inc. (NasdaqGS:OPCH) cancelled the acquisition of Amedisys, Inc. (NasdaqGS:AMED).

Investor sentiment improves as stock rises 19%

Option Care Health, Inc. (NasdaqGS:OPCH) entered into an agreement and plan of merger to acquire Amedisys, Inc. (NasdaqGS:AMED) for $3.2 billion.

Price target decreased by 8.5% to US$98.85

Option Care Health, Inc. (NasdaqGS:OPCH) entered into an agreement and plan of merger to acquire Amedisys, Inc. (NasdaqGS:AMED) for $3.2 billion.

Is Amedisys, Inc. (NASDAQ:AMED) Trading At A 41% Discount?

Does Amedisys (NASDAQ:AMED) Have A Healthy Balance Sheet?

Full year 2022 earnings: EPS exceeds analyst expectations

Amedisys, Inc. (NasdaqGS:AMED) announces an Equity Buyback for $100 million worth of its shares.

Amedisys (NASDAQ:AMED) Will Be Hoping To Turn Its Returns On Capital Around

Chairman & CEO exercised options and sold US$221k worth of stock

Amedisys, Inc. to Report Q4, 2022 Results on Feb 15, 2023

At US$83.54, Is It Time To Put Amedisys, Inc. (NASDAQ:AMED) On Your Watch List?

A Look At The Fair Value Of Amedisys, Inc. (NASDAQ:AMED)

Insufficient new directors

Amedisys, Inc. Names Scott Ginn as Acting Chief Operating Officer

Amedisys, Inc. Announces CEO Changes

High number of new directors

Capital Allocation Trends At Amedisys (NASDAQ:AMED) Aren't Ideal

Consensus EPS estimates fall by 16%

Price target decreased to US$126

Amedisys, Inc. Provides Earnings Guidance for the Year 2022

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Amedisys, Inc. to Report Q3, 2022 Results on Oct 26, 2022

Amedisys, Inc. Announces Resignation of David L. Kemmerly as Chief Legal and Government Affairs Officer

Is Now The Time To Look At Buying Amedisys, Inc. (NASDAQ:AMED)?

An Intrinsic Calculation For Amedisys, Inc. (NASDAQ:AMED) Suggests It's 38% Undervalued

Amedisys: ROIC, Tangible Book Value Each Softening

Consensus EPS estimates fall by 11%

Slowing Rates Of Return At Amedisys (NASDAQ:AMED) Leave Little Room For Excitement

Price target decreased to US$145

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Amedisys profit beats by $0.24, revenue misses by $25.23M, 2022 guidance below estimates

We Think Amedisys (NASDAQ:AMED) Can Stay On Top Of Its Debt

Price target decreased to US$160

Amedisys, Inc. to Report Q2, 2022 Results on Jul 27, 2022

Amedisys, Inc.(NasdaqGS:AMED) dropped from Russell 1000 Growth-Defensive Index

At US$115, Is It Time To Put Amedisys, Inc. (NASDAQ:AMED) On Your Watch List?

Price target decreased to US$174

Returns On Capital At Amedisys (NASDAQ:AMED) Have Stalled

First quarter 2022 earnings: EPS and revenues miss analyst expectations

High number of new directors

Amedisys, Inc. Announces Promotion of Nick Muscato as Chief Strategy Officer

Is Amedisys, Inc. (NASDAQ:AMED) Trading At A 40% Discount?

Amedisys, Inc. to Report Q1, 2022 Results on Apr 27, 2022

Does Amedisys (NASDAQ:AMED) Deserve A Spot On Your Watchlist?

Amedisys, Inc. (NasdaqGS:AMED) completed the acquisition of Assets of AssistedCare Home Health, Inc. and RH Homecare Services, LLC.

Amedisys, Inc. Announces Resignation of Richard A. Lechleiter from the Board of Directors

Investor sentiment improved over the past week

Price target decreased to US$184

Chairman & CEO exercised options and sold US$2.8m worth of stock

Full year 2021 earnings: EPS misses analyst expectations

Amedisys, Inc. (NasdaqGS:AMED) signed a definitive agreement to acquire Assets of AssistedCare Home Health, Inc.

Is Amedisys (NASDAQ:AMED) A Risky Investment?

Amedisys, Inc. (NasdaqGS : AMED) agreed to acquire Evolution Health, LLC from Emergency Medical Services LP Corporation.

Amedisys, Inc. to Report Q4, 2021 Results on Feb 23, 2022

Amedisys (NASDAQ:AMED) Shareholders Will Want The ROCE Trajectory To Continue

High number of new directors

Investor sentiment improved over the past week

Lead Independent Director recently bought US$141k worth of stock